User: Neurenati Therapeutics Inc.
Hirschsprung disease is a life-threatening condition characterized by the absence of nerve cells in the lower part of the gastrointestinal tract, leading to severe digestive issues, health complications, and potentially premature death. Our team is working on a groundbreaking treatment for this disease, building on our previous discovery that a biological compound called GDNF (Glial Cell Line-Derived Neurotrophic Factor) can stimulate the development of a new nervous system in the intestines of mouse models. This restoration of intestinal function has shown promise in improving both health and survival in these mice.
However, not all mice respond equally to GDNF therapy. While some show significant improvement, others do not respond fully or at all. The primary goal of this project is to identify specific microbes in the gut microbiome that may be linked to positive responses to GDNF treatment. Understanding these microbial associations could eventually allow us to tailor GDNF therapy, improving its effectiveness in clinical settings.
To achieve this, we will use advanced DNA sequencing techniques to analyze the microbial genomes present in the gut microbiomes of the treated mice. By building a comprehensive reference library of these microbial genomes, we will identify microbial patterns that correlate with favorable outcomes following GDNF treatment. These insights will inform the development of potential biomarkers that could be used to monitor treatment efficacy in human patients, paving the way for more personalized and effective therapies in future clinical trials.